Disialoganglioside GD2, (NH4+ salt)Disialoganglioside GD2, (NH4+ salt)
Move your mouse over image or click to enlarge

Disialoganglioside GD2, (NH4+ salt)


Gangliosides1 are acidic glycosphingolipids that form lipid rafts in the outer leaflet of the cell plasma membrane, especially in neuronal cells in the central nervous system.2 They participate in cellular proliferation, differentiation, adhesion, signal transduction, cell-to-cell interactions, tumorigenesis, and metastasis. The accumulation of gangliosides has been linked to several diseases including Tay-Sachs and Sandhoff disease and cancer. Disialoganglioside GD2 is normally found mostly in the central nervous system and in low amounts in peripheral nerves and skin melanocytes. However in various cancers aberrant glycosilation produces relatively high amounts of GD2 on tumor cell surfaces and has been shown to enhance tumor proliferation and metastasis. The relatively tumor specific expression of GD2 makes it a good candidate for immunotherapy using anti-GD2 antibodies and this approach has been actively pursued for the past several decades.3,4
Cat# Size Price Qty Buy
1527 0.5 mg £594.15

Additional Information

Property Value or Rating
Product Size 0.5 mg
Manufacturer Matreya, LLC
Empirical Formula C78H138N4O34 • 2NH3 (stearoyl)
CAS# 65988-71-8
Formula Weight 1710
Source semisynthetic
Purity 98+%
Analytical Methods TLC, MS, identity confirmed by MS
Natural Source Semi-synthetic|Animal/Rabbit
Solubility chloroform/methanol/DI water, 2:1:0.1; forms micellar solution in water
Physical Appearance A neat solid
Storage -20°C

1. L. Svennerholm, et al. (eds.), Structure and Function of Gangliosides, New York, Plenum, 1980 
2. T. Kolter, R. Proia, K. Sandhoff “Combinatorial Ganglioside Biosynthesis” J. Biol. Chem., Vol. 277:29 pp. 25859-25862, 2002 
3. M. Ahmed and N. Cheung “Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy” FEBBS Lett. Vol. 588 pp. 288-297, 2014 
4. M. Ahmed, J. Hu, and N. Cheung “Structure based refinement of a humanized monoclonal antibody that targets tumor antigen disialoganglioside GD2” Front. Immunol. Vol. 5(372) pp. 1-6, 2014

Related Documents